Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Scheduled Post-Infusion Medication for Pediatric ITP Patients Receiving IVIG
NCT04741139Phase 1Unknown
- Sponsor
- Baylor College of Medicine
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acetaminophen and diphenhydramine in immune thrombocytopenia (ITP), sponsored by Baylor College of Medicine. Primary endpoint: Percentage of Eligible Patients Agreeing to Enrollment at 12 months. Status: unknown.
02
Drugs
acetaminophendiphenhydramine
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04741139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04741139.